MOST试验中局部与中央判定的改良Rankin量表评分比较
MOST试验比较局部与中央判定的90天改良Rankin量表(mRS)评分,共378例有记录访视。局部与中央评分总体一致性极好(加权κ 0.87,95%CI 0.83-0.90)。使用局部mRS与中央判定时试验结论未变。作者认为在盲法终点评估下,急性卒中试验的中央mRS判定可能并非必需。
要点
- 局部与中央mRS评分总体一致性极好,加权κ 0.87(95%CI 0.83-0.90)。
- 基线mRS非零者一致性强度有非显著下降(mRS=0为0.87 vs mRS>0为0.80)。
- 使用局部mRS与中央判定时试验结论未改变。
核心结论
- 局部mRS评分在所有评估方式中与中央评分均显示强一致性。
- 作者认为在盲法终点评估下,急性卒中试验的中央mRS判定可能并非必需。
研究设计与样本
- MOST为3期、单盲、随机试验,评估阿加曲班、依替巴肽或安慰剂联合静脉溶栓。
- 主要结局为90天mRS评分,由盲法局部人员通过面对面视频记录采集,录像送中央判定者最终评分。
- 因SARS-CoV-2限制面对面访视,允许远程访谈。
- 514例参与者中378例有可用的记录访视(面对面视频121例、远程视频157例、远程音频100例)。
主要发现
- 局部评估者设盲率为96.8%,85.4%的访视使用了Rankin聚焦评估。
- 局部与中央mRS评分总体一致性极好,加权κ 0.87(95%CI 0.83-0.90)。
- 基线mRS=0者加权κ 0.87(95%CI 0.84-0.91),基线mRS>0者加权κ 0.80(95%CI 0.68-0.91),一致性强度下降但未达统计学显著。
- 使用局部mRS与中央判定时试验结论未改变。
关键数值与推荐
- 局部与中央mRS评分总体加权κ 0.87(95%CI 0.83-0.90)。
- 基线mRS=0者加权κ 0.87(95%CI 0.84-0.91),基线mRS>0者加权κ 0.80(95%CI 0.68-0.91)。
- 局部评估者设盲率96.8%,Rankin聚焦评估使用率85.4%。
临床怎么用
- 作者认为在盲法终点评估下,急性卒中试验的中央mRS判定可能并非必需。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The modified Rankin Scale (mRS) is a key measure of functional outcomes in stroke trials. To minimize variability, structured tools like the Rankin Focused Assessment and central adjudication are recommended. This study compares local versus centrally adjudicated mRS scores in the MOST trial (Multi-Arm Optimization of Stroke Thrombolysis). METHODS: MOST was a phase 3, single-blind, randomized trial evaluating argatroban, eptifibatide, or placebo in addition to intravenous thrombolysis. The primary outcome, 90-day mRS score, was gathered through in-person video recordings by blinded local personnel. Recordings were sent to central adjudicators for final scoring. As in-person visits became limited due to SARS-CoV-2, remote interviews were allowed. We hypothesized that local mRS scores would be moderately associated with central scores. Fleiss-Cohen quadratic weighted κ statistics were used to determine the strength of agreement. RESULTS: Out of 514 participants, 378 had recorded visits available (121 in-person video, 157 remote video, 100 remote audio). Local assessors were blinded 96.8% of the time and 85.4% of visits used the Rankin Focused Assessment. Overall agreement between local and central mRS scores was excellent (weighted κ, 0.87 [95% CI, 0.83-0.90]). A nonsignificant decrease in strength of agreement was noted for those with a nonzero baseline mRS (mRS score=0, 0.87 [95% CI, 0.84-0.91] versus mRS score >0, 0.80 [95% CI, 0.68-0.91]). Trial conclusions were unchanged when utilizing the local mRS versus central adjudication. CONCLUSIONS: Local mRS scores demonstrated strong agreement with central scores across all assessment modes. With blinded end point assessments, central mRS adjudication in acute stroke trials may not be necessary. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03735979.
引用
- Shawkat A, Barreto AD, Broderick JP, et al. Comparison of Local and Centrally Adjudicated Modified Rankin Scale Scores in the MOST Trial. Stroke. 2025. PMID: 40123511. doi:10.1161/STROKEAHA.124.049825
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。